The burden of progressive fibrotic interstitial lung disease across the UK.
Abstract
Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN
Author
Simpson, Thomas
Barratt, Shaney L
Beirne, Paul
Chaudhuri, Nazia
Crawshaw, Anjali
Crowley, Louise E
Fletcher, Sophie
Gibbons, Michael A
Hallchurch, Philippa
Horgan, Laura
Jakaityte, Ieva
Lewis, Thomas
McLellan, Tom
Myall, Katherine J
Miller, Ryan
Smith, David J F
Stanel, Stefan
Thillai, Muhunthan
Thompson, Fiona
Wallis, Timothy
Wu, Zhe
Molyneaux, Philip L
West, Alex G
Barratt, Shaney L
Beirne, Paul
Chaudhuri, Nazia
Crawshaw, Anjali
Crowley, Louise E
Fletcher, Sophie
Gibbons, Michael A
Hallchurch, Philippa
Horgan, Laura
Jakaityte, Ieva
Lewis, Thomas
McLellan, Tom
Myall, Katherine J
Miller, Ryan
Smith, David J F
Stanel, Stefan
Thillai, Muhunthan
Thompson, Fiona
Wallis, Timothy
Wu, Zhe
Molyneaux, Philip L
West, Alex G
Citations
Altmetric:
Date
2021-07-08
Type
Article
Subject
Respiratory medicine
Collections
Citation
Simpson T, Barratt SL, Beirne P, Chaudhuri N, Crawshaw A, Crowley LE, Fletcher S, Gibbons MA, Hallchurch P, Horgan L, Jakaityte I, Lewis T, McLellan T, Myall KJ, Miller R, Smith DJF, Stanel S, Thillai M, Thompson F, Wallis T, Wu Z, Molyneaux PL, West AG. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021 Jul 8;58(1):2100221. doi: 10.1183/13993003.00221-2021
Journal / Source Title
European Respiratory Journal
DOI
10.1183/13993003.00221-2021
PMID
33678609
Publisher
European Respiratory Society
Publisher’s URL
https://erj.ersjournals.com/